What causes Guillain‑Barré syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What Causes Guillain-Barré Syndrome

Guillain-Barré syndrome is caused by an aberrant autoimmune response triggered by preceding infections in approximately two-thirds of cases, with Campylobacter jejuni being the single most common infectious trigger, responsible for about one-third of all GBS cases. 1, 2

Primary Infectious Triggers

The pathogenesis of GBS centers on molecular mimicry, where the immune system generates antibodies against infectious pathogens that cross-react with peripheral nerve components, leading to nerve damage 1.

Bacterial Infections

  • Campylobacter jejuni (most common overall trigger):

    • Accounts for approximately 30-70% of GBS cases depending on geographic region 1
    • Predominantly triggers the axonal subtype of GBS (AMAN/AMSAN) 1
    • The mechanism involves molecular mimicry between C. jejuni lipo-oligosaccharides and human nerve gangliosides, producing cross-reactive antibodies that activate complement and damage nerves 1
    • Only 1 in 1,000-5,000 patients with C. jejuni infection develop GBS, as carbohydrate mimicry must be present in the bacterial strain 1
    • GBS following C. jejuni is typically more severe than other causes 2

  • Mycoplasma pneumoniae (5% of cases) 1

  • Haemophilus influenzae (linked to Miller Fisher syndrome in Asia) 1

Viral Infections

The demyelinating and sensorimotor forms of GBS are usually preceded by viral infections 1:

  • Cytomegalovirus (10-13% of cases) 1
  • Epstein-Barr virus (10% of cases) 1
  • Zika virus (associated with 20-fold increase during outbreaks, though only 2 in 10,000 infected develop GBS) 1
  • Hepatitis E virus (5% in children) 1
  • SARS-CoV-2 (possible association, with 77-80% showing demyelinating subtype, though epidemiological studies show conflicting results) 1

Geographic and Regional Variations

  • Upper respiratory tract infections are most common in Europe, North America, and parts of Asia (22-53% of cases) 1
  • Gastroenteritis predominates in India and Bangladesh (36-47% of cases) 1
  • Regional infections like dengue, malaria, and HIV have been associated with GBS in case reports from endemic areas 1

Immunopathogenesis

The key mechanism involves:

  1. Molecular mimicry between pathogen surface structures and nerve components
  2. Production of cross-reactive antibodies against gangliosides (GM1, GD1a, GQ1b)
  3. Complement activation leading to nerve damage
  4. Either demyelination (AIDP) or axonal injury (AMAN/AMSAN) depending on antibody specificity 1

Host Susceptibility Factors

Despite strong associations with infections, the overall risk of developing GBS after any single infection is very small. Contributing factors include 1:

  • Genetic polymorphisms in TNF and MBL2 genes
  • Nutritional status (malnutrition alters immune responses)
  • Specific pathogen strain characteristics (not all C. jejuni strains have the necessary carbohydrate mimicry)

Non-Infectious Triggers (Rare)

  • Vaccines: Only the 1976 swine flu vaccine showed convincing association (7.3-fold increased risk). Modern influenza vaccines show minimal risk (~1 additional case per million vaccinations) 3
  • Immunobiological agents: Tumor necrosis factor antagonists, immune checkpoint inhibitors (case series evidence only) 3
  • Surgery and malignancy: Temporal associations reported but lack clear biological rationale 3

Critical Clinical Pitfall

The absence of an antecedent illness does not exclude GBS, as approximately one-third of patients report no preceding infection, likely due to subclinical infections or unidentified triggers 3. The diagnosis remains clinical and should not be dismissed based solely on infection history.

References

2
Research

Triggers of Guillain-Barré Syndrome: Campylobacter jejuni Predominates.

International journal of molecular sciences, 2022

Related Questions

What is Guillain‑Barré syndrome?
What is the prognosis for Guillain‑Barré syndrome?
In Guillain‑Barré syndrome (GBS), what tidal volume threshold should be maintained and how frequently should it be monitored to prevent respiratory failure?
What validated predictive scoring system is used to assess the need for intubation in Guillain‑Barré syndrome?
What are the diagnostic criteria for Guillain‑Barré syndrome?
Which medications are strong CYP3A4 inhibitors and strong CYP3A4 inducers?
What is the preferred quinolone and its dose for an otherwise healthy adult with acute explosive diarrhea without red‑flag features?
Is it appropriate to combine fenofibrate with a statin in a patient with mixed dyslipidemia and triglycerides ≥500 mg/dL, and what precautions and monitoring are required?
In a 50-year-old man with a 5-year history of left ocular pain that has acutely worsened over the past 3 days without trauma, and only CT head (no MRI) is available, what is the most appropriate next step in management?
Is duloxetine safe for an 81-year-old woman with shoulder pain?
Can fluoxetine promote peripheral nerve regeneration after Guillain‑Barré syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.